Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a Healthcare company (Medical - Devices) with a market capitalization of $19.2B. The Maz Rating grades it against the other companies in its sector.
Zimmer Biomet Holdings, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $101.41, Zimmer Biomet Holdings, Inc. trades at 25.5x trailing earnings, 2.2x sales and 1.5x book value, with an EV/EBITDA of 11.5. Over the last twelve months it generated about $8.6B of revenue and $751M of net income. It runs a gross margin of 69.7%, an operating margin of 15.1% and a net margin of 9.0%. It shows return on equity of 6.1%, return on invested capital of 5.3% and a free cash flow yield of 8.6%. On the balance sheet: a debt-to-equity ratio of 0.59 and a current ratio of 1.46. Over the past 52 weeks the share price ranged from $79.12 to $112.55, with a beta of 0.47.
Zimmer Biomet Holdings, Inc. pays a dividend yielding 0.95%, with 24% of earnings paid out. Its Maz Dividend Score is 2.57 out of 5, ranked against the other dividend payers in its sector (Safety 3.70, Growth 1.70, Yield 3.10, Consistency 2.19).
42 Wall Street analyst ratings cover the stock: 18 Buy, 23 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Zimmer Biomet Holdings, Inc. (ZBH) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 40.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.22% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 40.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.15% / 33% · Receivables / Mkt Cap (36m) 9.78% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 40.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.15% / 33.33% · Receivables / Mkt Cap (24m) 9.78% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 32.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 1.98% / 33.33% · Receivables / Avg Assets (4Q) 7.62% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 31.9% / 33.33% · (Cash+ST Inv) / Total Assets 1.70% / 33.33% · (Cash+Recv) / Total Assets 9.41% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Zimmer Biomet Holdings, Inc. (ZBH) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
No. Zimmer Biomet Holdings, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
Zimmer Biomet Holdings, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.